Agoraphobia

Agoraphobia is an anxiety disorder characterised by marked fear or anxiety about two or more of the following: using public transportation; being in open spaces; being in enclosed spaces; standing in line or in a crowd; being outside the home alone. The feared situations are actively avoided, require a companion, or are endured with intense anxiety. The fear is out of proportion to the actual danger posed by the situation. References: DSM-5-TR, StatPearls (NCBI Bookshelf).

Agoraphobia is an anxiety disorder characterised by marked fear or anxiety about two or more of the following: using public transportation; being in open spaces; being in enclosed spaces; standing in line or in a crowd; being outside the home alone. The feared situations are actively avoided, require a companion, or are endured with intense anxiety. The fear is out of proportion to the actual danger posed by the situation. DSM-5-TR classifies agoraphobia as a separate disorder from panic disorder; the two can co-occur but each can be diagnosed independently. Agoraphobia often leads to severe functional impairment, including housebound states in extreme cases. This information is for psychoeducation only.

Core features: Marked fear or anxiety in >=2 of 5 situation types (public transport, open spaces, enclosed spaces, queues/crowds, outside home alone). The situations are feared because escape might be difficult or help unavailable if panic or panic-like symptoms occur. The situations almost always provoke fear/anxiety. They are actively avoided, require a companion, or are endured with intense distress. The fear/anxiety is out of proportion to the actual danger. Symptoms persist >=6 months. Cause significant distress or functional impairment. Additional features: anticipatory anxiety, safety behaviours (always carrying water/phone, sitting near exits), reassurance-seeking, agoraphobic avoidance expanding over time if untreated.

Biological: prior panic attacks or panic disorder; female sex (2-3x more common in women); genetic vulnerability to anxiety. Psychological: anxiety sensitivity (fear of anxiety sensations); catastrophic interpretations of bodily sensations; tendency toward behavioural avoidance; introversion. Environmental: stressful life events preceding onset; history of physical illness causing embarrassment or helplessness in public (e.g., fainting, vomiting, bowel problems); traumatic experiences in public settings. The disorder often begins with panic attacks that become associated with specific situational contexts; avoidance develops and generalises.

Agoraphobia is fundamentally a disorder of conditioned fear and avoidance. An initial panic attack in a public setting creates fear associations with contextual cues. Classical conditioning generalises fear to similar contexts. Negative reinforcement: avoidance reduces anxiety temporarily, strengthening the avoidance behaviour and preventing extinction. Anxiety sensitivity (fear of fear) amplifies this cycle. Neurobiologically: hyperactivation of the amygdala (threat detection), underactivation of the prefrontal cortex (extinction), and disrupted interception (misinterpretation of bodily sensations). The HPA axis shows elevated cortisol

reactivity.

12-month prevalence: ~1.7% in adults; lifetime prevalence ~3.5%. More common in women (2-3x male rate). Typical onset: late adolescence to mid-20s, though can occur at any age. Onset after age 40 should prompt evaluation for medical causes. Approximately two-thirds of cases are comorbid with panic disorder. Other common comorbidities: other specific phobias, social anxiety disorder, generalised anxiety disorder, MDD, and substance use disorders. Agoraphobia without panic disorder accounts for ~30% of cases. Chronic and unremitting without treatment; spontaneous remission is uncommon.

Shares neurobiological features with other anxiety disorders. Fear circuit dysregulation: amygdala hyperreactivity, vmPFC hypoactivation (impaired fear extinction), anterior insula hyperactivation (interoceptive hypersensitivity). Serotonin and norepinephrine systems are implicated (explaining SSRI/SNRI efficacy). The insula and anterior cingulate cortex contribute to misinterpretation of bodily sensations. Interoceptive conditioning: neutral bodily sensations (heart rate increase, breathlessness) become conditioned stimuli for panic, fuelling avoidance. GABAergic deficits explain the immediate anxiolytic effects of benzodiazepines.

Clinical interview: detailed history of feared situations, avoidance pattern, duration, triggers, and functional impact. Assessment of panic attacks (frequency, severity, content). Rating scales: Agoraphobic Cognitions Questionnaire (ACQ); Mobility Inventory for Agoraphobia (MIA) - assesses avoidance with and without companion; Panic Disorder Severity Scale (PDSS). Physical exam: cardiac, thyroid, and vestibular assessment to exclude medical mimics. Rule out substance-induced anxiety. Functional assessment: graded from mild restriction to completely housebound.

DSM-5-TR criteria: A. Marked fear/anxiety in >=2 of 5 situations (public transport, open spaces, enclosed spaces, queues/crowds, outside home alone). B. Person fears/avoids because of thoughts that escape might be difficult or help unavailable during panic-like symptoms. C. Situations almost always provoke fear/anxiety. D. Actively avoided, require companion, or endured with intense distress. E. Fear out of proportion to actual danger. F. Duration >=6 months. G. Significant distress/impairment. H. If medical condition present, the anxiety is excessive. I. Not better explained by another mental disorder. Note: Agoraphobia is diagnosed irrespective of panic disorder. Both can be diagnosed if criteria are met. ICD-11: Agoraphobia (6B22).

Agoraphobic Cognitions Questionnaire (ACQ): assesses catastrophic cognitions about bodily sensations. Mobility Inventory for Agoraphobia (MIA): rates avoidance of 27 situations alone vs. accompanied. Panic Disorder Severity Scale (PDSS): 7-item clinician-rated scale for panic disorder and agoraphobia severity. Fear and Avoidance Hierarchy: patient-generated list of feared situations ranked by distress - essential for exposure therapy planning. SCID-5/MINI for structured diagnosis and comorbidity assessment.

Panic disorder without agoraphobia: panic attacks without situational avoidance. Social anxiety disorder: avoidance of social/performance situations (fear of embarrassment), not fear of escape. Specific phobias: fear limited to specific objects/situations. Generalised anxiety disorder: pervasive worry, not situation-specific. PTSD: avoidance of trauma cues. Separation anxiety: avoidance driven by fear of separation from attachment figures. Medical causes: vestibular disorders, cardiac arrhythmias, hyperthyroidism can produce panic-like symptoms requiring situational avoidance.

Treatment of Agoraphobia is primarily psychotherapeutic, with pharmacotherapy as an adjunct for moderate-to-severe cases. Psychotherapy: Cognitive-behavioural therapy (CBT) with graded exposure is the gold-standard treatment. The core component is systematic, gradual exposure to feared and avoided situations (crowds, public transport, open spaces, being away from home) while preventing escape and avoidance behaviours. Cognitive restructuring addresses catastrophic beliefs about panic symptoms and their consequences. Interoceptive exposure targets fear of bodily sensations. Applied relaxation and breathing retraining are commonly included. Virtual reality exposure therapy is an emerging modality. Treatment typically involves 12-16 sessions, with significant gains often seen by session 8. Pharmacotherapy: SSRIs (sertraline, paroxetine, escitalopram) and SNRIs (venlafaxine) are first-line pharmacological treatments and are effective for reducing agoraphobic avoidance and panic symptoms. Onset of therapeutic effect takes 4-6 weeks. Benzodiazepines provide rapid relief but carry risks of dependence and cognitive impairment; they are best used short-term or as bridging therapy while waiting for SSRI onset.

Tricyclic antidepressants (imipramine, clomipramine) are effective but have more side effects. Combined Treatment: The combination of CBT and medication often produces better outcomes than either alone, particularly for severe cases. Long-term maintenance with CBT-learned skills helps prevent relapse after medication discontinuation.

Without treatment, agoraphobia typically follows a chronic, worsening course with progressive expansion of avoidance. With CBT: 60-80% achieve significant improvement; 40-50% achieve full remission. Long-term outcomes are better with combined CBT + pharmacotherapy and when treatment is initiated early. Relapse following medication discontinuation is high without psychological treatment. Comorbid panic disorder worsens prognosis. Severity predictors: greater avoidance, longer duration, comorbid depression, and inadequate social support predict poorer outcomes.

Severe functional restriction including housebound state. Dependency on others for basic activities. Unemployment and financial difficulties. Social isolation and relationship problems. MDD comorbidity (develops in ~50% of chronic agoraphobia). Substance use (alcohol/benzodiazepines for anxiety self-medication). Avoidance-based maintenance cycles that progressively restrict life. Physical health neglect from inability to access medical care.

No proven primary prevention. Early intervention following first panic attacks may prevent development of agoraphobic avoidance. Patient education: avoidance maintains and worsens agoraphobia; gradual, planned approach to feared situations (exposure) is the key treatment principle; anxiety will peak and naturally subside without harm; the goal of exposure is to learn that feared consequences do not occur and anxiety is manageable. Involve family in treatment to avoid inadvertently reinforcing avoidance through over-accommodation.

Historically considered 'panic disorder with agoraphobia.' The term 'agoraphobia' derives from Greek 'agora' (marketplace, public gathering place). Westphal described 'agoraphobia' as a distinct clinical entity in 1871. Freud attributed it to repressed sexual conflict (anxiety neurosis). Behavioural models from the 1950s-70s explained maintenance through avoidance (Mowrer's two-factor theory). DSM-5 (2013) separated agoraphobia from panic disorder, allowing independent diagnosis.

Agoraphobia is often misunderstood as simply 'fear of leaving the house.' Stigma around the condition can delay help-seeking. Housebound individuals may be socially invisible. Online communities and telehealth have opened access to treatment for severely agoraphobic individuals. COVID-19 pandemic (2020-21) exacerbated agoraphobic symptoms in vulnerable individuals due to prolonged home isolation and heightened threat perception.

Internet-delivered and app-based CBT for agoraphobia and panic disorder. Virtual reality exposure therapy (VRET): computer-simulated environments for exposure practice. Augmentation of CBT with D-cycloserine (NMDA partial agonist to facilitate fear extinction learning). Attention bias modification training. Neuroimaging biomarkers predicting treatment response.

APA. (2022). DSM-5-TR. APA Publishing. Hofmann SG & Smits JAJ. (2008). CBT for agoraphobia. J Clin Psychol, 64, 660-669. Sadock BJ, et al. (Eds.). (2024). Kaplan & Sadock's Comprehensive Textbook of Psychiatry (11th ed.). Wolters Kluwer. StatPearls. Agoraphobia. NCBI Bookshelf NBK554387.

StatPearls: Agoraphobia (NCBI Bookshelf)

NIMH: Anxiety Disorders

Crisis resources: 988 (US); Crisis Text Line: text HOME to 741741.